Drugs / Duligotuzumab
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01986166 | Nov 2013 → Jan 2016 | neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01911598 | Sep 2013 → Jun 2017 | head and neck cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01207323 | Nov 2010 → Dec 2013 | epithelial neoplasm | Genentech, Inc. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT01652482 | Oct 2012 → Nov 2014 | colorectal cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01577173 | Jul 2012 → Jun 2015 | head and neck cancer | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Duligotuzumab | “Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer.” PMID 29506988 ↗ Mar 2018 |
| Known as | Duligotumab | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137345 ↗ |
| Known as | MEHD7945A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01652482 ↗ |
| Known as | RG-7597 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137345 ↗ |
| Action | Inhibit | “Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A)” PMID 29506988 ↗ Mar 20181“Receptor tyrosine-protein kinase erbB-3 inhibitor” CHEMBL3137345 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3137345 ↗ |
| Route | Intravenous | “Participants will receive intravenous (IV) infusion of MEHD7945A in escalating doses Q2W” NCT01207323 ↗ |
| Target | EGFR | “Duligotuzumab is a dual-action antibody directed against EGFR and HER3.” PMID 29506988 ↗ Mar 2018 |
| Target | ERBB3 | “Receptor tyrosine-protein kinase erbB-3 inhibitor” CHEMBL3137345 ↗ |